In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharmasset, Inc.

http://www.pharmasset.com/

Latest From Pharmasset, Inc.

Deal Watch: Moderna, Immactics Team Up To Combine mRNA Technology With Cancer Cell Therapy

Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.

Deal Watch Business Strategies

Deal Watch: Novartis, Ionis Team Up Again In Cardiovascular Disease

Plus deals involving ProQR/ Thea, Aeglea/Immedica, Ayala/Biolight, Quince/EryDel, ImmunoBiochem/ImmunoGen and GSK/LimmaTech, as well as deals in brief.

Deal Watch Business Strategies

Minute Insight: Coloplast Adds Icelandic Wound Care Innovator Kerecis For $1.3BN

Coloplast expects Kerecis' rapid growth to justify the high price of the acquisition. The Icelandic company's skin-substitute products are made from minimally processed cod skins.

Minute Insights M & A

China’s KRAS Race: Homegrown Contenders Play Catch-Up

The sizzling race for China’s first approved KRAS inhibitor has seen Amgen/BeiGene’s Lumakras drop out and Mirati/Zai Lab’s Krazati lag in a confirmatory Phase III trial, while domestic fast-followers are in the meantime eyeing their first approval filings by the end of this year.

China Clinical Trials
See All

Company Information

UsernamePublicRestriction

Register